{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-274580","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.780020+00:00","generated_at":"2026-06-08T06:44:03.122393+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"DBV reports positive 2-year OLE results for Viaskin Peanut in toddlers; 81.3% reach 1,000 mg eliciting dose","bullets":["After 24 months, 81.3% of subjects reached eliciting dose >=1,000 mg peanut protein vs 64.2% at 12 months.","55.9% completed the 3,444 mg DBPCFC without meeting stopping criteria, up from 30.7% at 12 months.","No treatment-related anaphylaxis or serious TEAEs in second year; local application site reactions decreased.","Placebo crossover group (12 months VP250) showed 62.7% reaching >=1,000 mg ED; single anaphylaxis event.","Results to be presented at ACAAI Nov 11; investor call/webcast Nov 9 at 5pm ET."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-274580","json":"https://secwatch.observer/filing/0001193125-23-274580.json","markdown":"https://secwatch.observer/filing/0001193125-23-274580.md","text":"https://secwatch.observer/filing/0001193125-23-274580.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523274580/0001193125-23-274580-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312523274580/d286743d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:44:03.122393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}